Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life: V-HeFT II

T. S. Rector, G. Johnson, W. B. Dunkman, G. Daniels, L. Farrell, A. Henrick, B. Smith, J. N. Cohn

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Background. Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate. Methods and Results. The questionnaires were completed at baseline and at 3 months, 6 months, and subsequently every 6 months during follow-up, which averaged 2.5 years (range, 0.5-5.7 years). Data from the questionnaires were reliable as indicated by correlation coefficients between repeated baseline scores of 0.88 and 0.87. Both treatment groups showed a progressive deterioration in quality of life as measured by both questionnaires. The questionnaire scores of the two treatment groups were not significantly different at any follow-up visit. Furthermore, there were no differences between treatments among subgroups defined by baseline questionnaire scores, peak oxygen consumption, ejection fraction, previous vasodilator use, and plasma norepinephrine concentration. Conclusions. Although several factors may limit the generalization of these results, the lack of a difference with regard to patients' quality of life is an important consideration for the evaluation of the relative therapeutic efficacy of these vasodilators.

Original languageEnglish (US)
JournalCirculation
Volume87
Issue number6 SUPPL. VI
StatePublished - Jun 1993

Fingerprint

Isosorbide Dinitrate
Hydralazine
Enalapril
Heart Failure
Quality of Life
Vasodilator Agents
Therapeutics
Oxygen Consumption
Surveys and Questionnaires
Norepinephrine
Randomized Controlled Trials

Keywords

  • Clinical trials
  • Heart failure
  • Quality of life
  • Questionnaires

Cite this

Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life : V-HeFT II. / Rector, T. S.; Johnson, G.; Dunkman, W. B.; Daniels, G.; Farrell, L.; Henrick, A.; Smith, B.; Cohn, J. N.

In: Circulation, Vol. 87, No. 6 SUPPL. VI, 06.1993.

Research output: Contribution to journalArticle

Rector, TS, Johnson, G, Dunkman, WB, Daniels, G, Farrell, L, Henrick, A, Smith, B & Cohn, JN 1993, 'Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life: V-HeFT II', Circulation, vol. 87, no. 6 SUPPL. VI.
Rector, T. S. ; Johnson, G. ; Dunkman, W. B. ; Daniels, G. ; Farrell, L. ; Henrick, A. ; Smith, B. ; Cohn, J. N. / Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life : V-HeFT II. In: Circulation. 1993 ; Vol. 87, No. 6 SUPPL. VI.
@article{69ab62e0d57e40f6be45d5868cdf2290,
title = "Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life: V-HeFT II",
abstract = "Background. Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate. Methods and Results. The questionnaires were completed at baseline and at 3 months, 6 months, and subsequently every 6 months during follow-up, which averaged 2.5 years (range, 0.5-5.7 years). Data from the questionnaires were reliable as indicated by correlation coefficients between repeated baseline scores of 0.88 and 0.87. Both treatment groups showed a progressive deterioration in quality of life as measured by both questionnaires. The questionnaire scores of the two treatment groups were not significantly different at any follow-up visit. Furthermore, there were no differences between treatments among subgroups defined by baseline questionnaire scores, peak oxygen consumption, ejection fraction, previous vasodilator use, and plasma norepinephrine concentration. Conclusions. Although several factors may limit the generalization of these results, the lack of a difference with regard to patients' quality of life is an important consideration for the evaluation of the relative therapeutic efficacy of these vasodilators.",
keywords = "Clinical trials, Heart failure, Quality of life, Questionnaires",
author = "Rector, {T. S.} and G. Johnson and Dunkman, {W. B.} and G. Daniels and L. Farrell and A. Henrick and B. Smith and Cohn, {J. N.}",
year = "1993",
month = "6",
language = "English (US)",
volume = "87",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6 SUPPL. VI",

}

TY - JOUR

T1 - Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life

T2 - V-HeFT II

AU - Rector, T. S.

AU - Johnson, G.

AU - Dunkman, W. B.

AU - Daniels, G.

AU - Farrell, L.

AU - Henrick, A.

AU - Smith, B.

AU - Cohn, J. N.

PY - 1993/6

Y1 - 1993/6

N2 - Background. Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate. Methods and Results. The questionnaires were completed at baseline and at 3 months, 6 months, and subsequently every 6 months during follow-up, which averaged 2.5 years (range, 0.5-5.7 years). Data from the questionnaires were reliable as indicated by correlation coefficients between repeated baseline scores of 0.88 and 0.87. Both treatment groups showed a progressive deterioration in quality of life as measured by both questionnaires. The questionnaire scores of the two treatment groups were not significantly different at any follow-up visit. Furthermore, there were no differences between treatments among subgroups defined by baseline questionnaire scores, peak oxygen consumption, ejection fraction, previous vasodilator use, and plasma norepinephrine concentration. Conclusions. Although several factors may limit the generalization of these results, the lack of a difference with regard to patients' quality of life is an important consideration for the evaluation of the relative therapeutic efficacy of these vasodilators.

AB - Background. Two new questionnaires concerning the quality of life of patients with heart failure were used in a randomized, controlled trial to determine if the patients' perceptions of the effects of enalapril on their daily activities and sense of well-being were different from those of a group treated with hydralazine and isosorbide dinitrate. Methods and Results. The questionnaires were completed at baseline and at 3 months, 6 months, and subsequently every 6 months during follow-up, which averaged 2.5 years (range, 0.5-5.7 years). Data from the questionnaires were reliable as indicated by correlation coefficients between repeated baseline scores of 0.88 and 0.87. Both treatment groups showed a progressive deterioration in quality of life as measured by both questionnaires. The questionnaire scores of the two treatment groups were not significantly different at any follow-up visit. Furthermore, there were no differences between treatments among subgroups defined by baseline questionnaire scores, peak oxygen consumption, ejection fraction, previous vasodilator use, and plasma norepinephrine concentration. Conclusions. Although several factors may limit the generalization of these results, the lack of a difference with regard to patients' quality of life is an important consideration for the evaluation of the relative therapeutic efficacy of these vasodilators.

KW - Clinical trials

KW - Heart failure

KW - Quality of life

KW - Questionnaires

UR - http://www.scopus.com/inward/record.url?scp=0027278224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027278224&partnerID=8YFLogxK

M3 - Article

C2 - 8500243

AN - SCOPUS:0027278224

VL - 87

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6 SUPPL. VI

ER -